Inherited Breast & Ovarian Cancer Screening Test (BRCA1&2)

Suitable for female of all age groups, especially those with family history in breast/ ovarian cancers
Product Code: OBB
i h


  • Breast cancer is the THIRD most deadly cancer among women in Hong Kong, second only to lung cancer and colorectal cancer
  • According to the latest 2020 study, it is estimated that more than 5 million people in China carry BRCA disease-causing gene mutations
  • Taking Asians as an example, the presence of a disease-causing mutation in the BRCA gene represent a 87% chance of developing breast cancer
  • In recent years, many studies have pointed out that BRCA1&2 genes are closely related to a variety of cancers. Disease-causing mutations in the BRCA gene will cause the DNA repair mechanism to fail and increase the risk of cancer
  • If there is any inherited mutation from either of BRCA1 and BRCA2 genes, cells are more likely to divide and change rapidly, which can lead to developing cancer
  • BRCA genes mutation coverage rate is up to 90%
  • This screening test has gained a very good performance in the Proficiency testing program provided by the College of American Pathologist (CAP)


  • It maps the risk of getting inherited breast & ovarian cancers.
  • It allows people to start early prevention. (E.g. Changing your daily diet or performing a more intensive health check-up).
  • Sharing the result with family members. If the person carriers BRCA mutation(s), her family member has 50% chance inherits the same mutation(s).
  • Result is beneficial for a lifetime. One-off blood test in a lifetime.


  • 6ml EDTA Blood

Reporting Time: 

  • Around 7-10 working days


  • No transfusion of blood 1 month before the test, no organ transplantation

Professional report interpretation via phone provided by genetics consultant


  1. E.R. Copson et al. (2018). Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 19:169-180
  2. K. Alsop et al. (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 30(21):2654-2663
  3. D.J. Gallagher et al. (2010). Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research. 16(7):2115-2121
  4. B.L. Niell et al. (2004). BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer. Journal of the National Cancer Institute. 96(1):15-21
  5. S. Holter et al. (2015). Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology. 33(28):3124-3129
  6. Department of Health (HKSAR)